Press Room

Event

DDL 2024 - Drug Delivery to the Lungs Conference

Start

Wednesday, December 11, 2024 - 08:00

End

Friday, December 13, 2024 - 17:00

Location: Edinburgh, Scotland

Booth Number: No. 168

Hovione is present at DDL Drug Delivery to the Lungs on December 2024, know more about the event and contact us to schedule a meeting

Hovione is excited to participate in the DDL Conference 2024, the Premier International Pulmonary & Nasal Drug Delivery Conference, from December 11-13 in Edinburgh.

Visit Hovione - Booth no. 168

Don't miss the opportunity to engage with our experts and learn more about our complete One-Site Solution that ensures that your inhalation and nasal therapies are engineered for success from start to finish.

Join Hovione Presentation

Thursday 12 December | Session 5 | 15:05 – 15:20

Finalists of The Pat Burnell Young Investigator Award

Paper Title: In vitro-In vivo Correlations (IVIVC) of Amorphous Solid Dispersions for Nasal Delivery

Patrícia Henriques, Scientist, R&D Inhalation and Advanced Drug Delivery

Abstract

Amorphous solid dispersions (ASD) for nasal delivery offer the opportunity to increase drug release performance, while using polymers with mucoadhesive properties. In spite of the current knowledge on formulation and characterization of nasal powders, scarce studies evaluate the potential of ASD. Additionally, the lack of translation between different in vitro methodologies and the lack of correlations between in vitro and in vivo results compromise the accurate and effective development of nasal powders.

Herein, spray dried ASD were manufactured and evaluated regarding in vitro drug release, ex vivo permeation and in vivo pharmacokinetic profile in Wistar rats. The results showed that ASD obtained by spray drying are able to improve drug release and permeation, ultimately resulting in faster drug absorption. This indicates that ASD for nasal delivery of poorly soluble drugs could be a suitable strategy to provide a faster onset of action. Additionally, the in vitro-in vivo correlations (IVIVC) between in vitro/ex vivo and in vivo pharmacokinetic parameters (t_max, C_max and AUC_1h), support the use of Franz diffusion cells to study drug release and permeation of nasal powder formulations.

Key learnings:

ASD of poorly soluble drugs for nasal delivery are a suitable strategy to provide a fast onset of action;
In vitro-in vivo correlations (IVIVC) are a valuable tool to support the use of in vitro methodologies as well as to guide formulation and process development.

Join Hovione Posters

Poster 81

Title: Dry Powder Antibody Formulations for Inhalation: Finding the Sweet Spot between High Dose and Protein Stability

Patrícia Henriques, Scientist, R&D Inhalation and Advanced Drug Delivery

Poster 110

Title: Breaking New Ground on Nasal Powders Performance Characterisation: Formulation & Device Integration

António Serôdio, Analytical Scientist, R&D Projects

Special Poster - Pat Burnell Nominee, Strathblane Foyer

Title: In vitro - In vivo Correlations (IVIVC) of Amorphous Solid Dispersions for Nasal Delivery

Patrícia Henriques, Scientist, R&D Inhalation and Advanced Drug Delivery

More about Inhalation and Nasal at Hovione

Find more about DDL 2024.

Let's discuss your project together.

Also in the Press Room

See All

A mechanical engineering graduate, this Frenchman is the CEO of the Portuguese pharmaceutical contract manufacturer Hovione. Still owned by the founding family, the company was awarded the 2025 ‘Léonardo de Vinci’ Prize, which recognizes the innovative and successful succession planning of family businesses. With an international career behind him, Jean-Luc Herbeaux is almost more fluent in English than in his native language. At 58, this Frenchman with iceberg-blue eyes is the CEO of Hovione. Founded in the late 1950s, this Portuguese group, with 100% family ownership, has just received the ‘Léonardo de Vinci’ Prize, which highlights entrepreneurial successes tinged with family legacy. While this mid-sized company with a turnover of €500 million maintains a low profile, its pharmaceutical contract manufacturing business is just as obscure to the general public. "Yet, the market for contract manufacturers, or 'contract development manufacturing organizations,' is worth $200 billion", emphasizes the CEO, who has been working in this microcosm for two decades. 500 patents Aware of the stakes, he does not deny "the pharma industry's dependence on Indian and Chinese capabilities". "The fact remains that the trend is toward the regionalization of supply chains, with European manufacturers producing for the Old Continent, American manufacturers for their own market, and so on", he says. And to highlight the foresight of Diane and Ivan Villax, the founding couple, "who thought globally from the very beginning". As a result, the group, with its 500 patents, has factories in China, the United States, and Ireland, without neglecting its home territory. This is evident by the site currently under construction on the banks of the Tagus River, following a €200 million investment. "The heavy engineering and compliance aspects are being finalized, "he explains, emphasizing that this highly regulated sector "is under a microscope". He knows this all too well, as Hovione claims to be involved in 5 to 10% of the drugs approved each year by the FDA, the American drug regulatory agency. Professor from Houston to Japan “In this small world, having a good image is important: this is the case with Jean-Luc, passionate about his work, but who knows how to demystify things”, observes Elie Vannier, former chairman of the board of Hovione. He adds that having an international profile is a strength “in this ecosystem where talent and clients are international”. For his part, Jean-Luc retains from his numerous flights “a taste for films of all genres and from all countries”. The son of an administrative employee in secondary schools and an auto insurance expert, the youngest of three children moved around according to his parents' job transfers. He was born in Meaux, grew up in Chartres, and attended the University of Technology of Compiègne, “which already offered programs abroad”. Thus, he left a mechanical engineering internship at a Dior perfume factory to join the University of Houston in Texas, "carrying a 20 kg backpack". Despite his then-limited command of English, he earned a doctorate, became a professor, and met an American woman who would become his wife and the mother of their two children. Next came the University of Kanazawa in Japan. Alas! Disappointed by the academic world, "where you have to fight to get resources", he succumbed to the allure of industry and joined the American chemical company Rohm and Haas, which had fallen under the control of the German company Evonik. 80 million patients He spent twenty years there, in Germany and Singapore, before "accepting the offers from headhunters". He then accepted Hovione's offer, who appointed him Chief Operating Officer in 2020, then CEO two years later, making him the first CEO not from the founding family. The family remains the sole shareholder, which earned the company the ‘Léonardo de Vinci’ Prize, created by the Association Les Hénokiens and the Clos Lucé. Having settled near Lisbon, he substituted walking for combat sports, "having been burned by the injuries of some friends". He also mentioned that Hovione, whose clients include 19 of the world's 20 largest pharmaceutical companies, helps treat more than 80 million patients. (Translated version) Read the original and full article in French on LesEchos.fr

Article

Les Echos, 2 December 2025

Jean-Luc Herbeaux aims to boost the growth of the pharmaceutical group Hovione

Dec 02, 2025

The CDMO’s New Jersey manufacturing site expansion will eventually cover more than 200,000 square feet. Portugal-based contract development and manufacturing organisation (CDMO) Hovione has completed an initial $100 million investment round in its East Windsor, New Jersey site. Once completed it will increase the facility’s footprint to more than 200,000 square feet and more than double its capacity for spray drying. Hovione CEO Jean-Luc Herbeaux said: “Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the US, we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.” Spray drying is an increasingly important particle engineering technology for improving drug bioavailability through the amorphous solid dispersion (ASD) that can address bioavailability or crystallisation challenges. The initial phase of Hovione’s expansion will include a 31,000-square-foot building to house two size-3 spray dryers (PSD-3) designed for ASD production. Construction at the New Jersey site is already underway and the company plans to start GMP operations in the second quarter of 2026. The initiative is part of Hovione’s long-term strategy to grow its US operations and enhance its integrated drug substance, drug product intermediate and drug product capabilities. Herbeaux said: “This investment addresses growing customer demand for US-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.” The company’s New Jersey expansion fits into its wider international growth plan that also includes capacity investments in Ireland and Portugal as it seeks to create a network of autonomous sites spanning the development and commercialisation of APIs, drug product intermediates and drug products. Read the full article at EuropeanPharmaceuticalReview.com

Press Clipping

European Pharmaceutical Review, 4 November 2025

Hovione doubles spray drying capacity with $100m US investment round

Nov 04, 2025

US-base manufacturing and the continued rise of peptides were among the key themes for CDMOs at CPHI Frankfurt 2025. Andrew Warmington reports. Hovione announced during this show that it has completed an initial $100 million investment phase in the expansion of its manufacturing footprint in East Windsor, New Jersey. The company was one of the first European CDMOs to set up in the US back in 2002. CEO Jean-Luc Herbeaux said that when he took over the role four years ago, Hovione's footprint in the US was limited and the site was reaching capacity limitations. (...) Read the full article on SpecChemOnline.com

Article

Speciality Chemicals, Nov./Dec. 2025